Bisantrene Combination for Resistant AML
Phase 2 Unknown
29 enrolled
Venetoclax Plus RIC Regimen Allo-HSCT for Elderly Patients With High-risk Myeloid Malignancies
Phase 2 Unknown
50 enrolled
Clinical Study of Venetoclax Combined With CAG in the Treatment of Refractory/Relapsed Acute Myeloid Leukemia
Phase 2 Unknown
52 enrolled
Plerixafor Plus Donor Lymphocyte Infusion for Relapsed Acute Leukemia After Allo-HSCT
Phase 2 Unknown
28 enrolled
Safety and Efficacy of Unrelated Umbilical Cord Blood Microtransplantation in Patients With AML
Phase 2 Unknown
20 enrolled
Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
Phase 2 Unknown
200 enrolled
MoTD
Phase 2 Unknown
400 enrolled
Study of Selinexor Combined With Chidamide in Relapsed/Refractory Acute Leukemia (AML) Patients
Phase 2 Unknown
42 enrolled
Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Myeloid Leukemia and Myelodysplastic Syndromes Undergoing Allo-HSCT
Phase 2 Unknown
70 enrolled
Phase 2, Open-Label, Single Arm Study, With BST-236 in Adults With R/R AML or Higher-Risk MDS
Phase 2 Unknown
40 enrolled
Pyronaridine in Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML)
Phase 2 Unknown
200 enrolled
Oral Arsenic Trioxide for NPM1-mutated AML
Phase 2 Unknown
50 enrolled
Study of Azacitidine Combined With Homoharringtonie Based Regimens in AML
Phase 2 Unknown
100 enrolled
Combination of Venetoclax, Hypomethylation Agent and Low-dose Cytarabine as a Salvage Therapy for Acute Myeloid Leukemia
Phase 2 Unknown
52 enrolled
Study of Chidamide Combined With Cladribine in Refractory/Relapsed Acute Myeloid Leukemia
Phase 2 Unknown
31 enrolled
Venetoclax and Azacitidine for the Management of Molecular Relapse/Progression in Adult NPM1-mutated Acute Myeloid Leukemia
Phase 2 Unknown
35 enrolled
Eltrombopag Olamine in Improving Platelet Recovery in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy
Phase 2 Unknown
31 enrolled 14 charts
Individualized Induction Therapy for Non-elderly Acute Myeloid Leukemia Patients With Adverse Risk Features
Phase 2 Unknown
42 enrolled
Sodium Stibogluconate in the MDS/AML With One of the 65 Defined p53 Mutations
Phase 2 Unknown
5 enrolled
IA14 Induction in Young Acute Myeloid Leukemia
Phase 2 Unknown
42 enrolled
Aza-Ven Followed by Reduced Toxicity Conditioning Regimen (MBF) as Salvage Therapy for Refractory AML.
Phase 2 Unknown
23 enrolled
The Use of Decitabine as Induction Therapy for Acute Myeloid Leukemia With Complex and/or Monosomal Karyotype
Phase 2 Unknown
20 enrolled
Vidaza and Valproic Acid Post Allogeneic Transplant for High Risk AML and MDS
Phase 2 Unknown
50 enrolled
A Phase 2 Study of Venetoclax in Combination With Low-dose HHT, G-CSF, and AZA as First-line Treatment for Newly Diagnosed Elderly AML Patients Unfit for Intensive Chemotherapy
Phase 2 Unknown
100 enrolled
Efficacy and Safety of Cladribine in Combination With CAG in Newly Diagnosed Unfit Patients With AML
Phase 2 Unknown
34 enrolled
Combination of Quizartinib and Omacetaxine Mepesuccinate for AML Carrying FLT3-ITD
Phase 2 Unknown
40 enrolled
Combined Inhibition of PD-1 and DNA Hypomethylating Agent +/- Chemotherapy in High-risk AML or Elderly Patients With AML Who Are Unfit for Intensive Chemotherapy
Phase 2 Unknown
55 enrolled
A Clinical Trail of Demethylation Drug Combined With Chemotherapy in Intermediate-risk AML
Phase 2 Unknown
100 enrolled
Combined PD1 Inhibitor and Decitabine in Elderly Patients With Relapse and Refractory Acute Myeloid Leukemia
Phase 2 Unknown
29 enrolled
PRO-DLI
Phase 2 Unknown
124 enrolled
Chemo Sensitization Before Hematopoietic Stem Cell Transplantation in Patients With Acute Leukemia in Complete Remission
Phase 2 Unknown
20 enrolled
Irradiation-based Myeloablative Conditioning Followed by Treg/Tcon Immunotherapy in HSCT
Phase 2 Unknown
80 enrolled
Cladribine in Combination With CAG in Patients With Refractory/Relapsed Acute Myeloid Leukemia
Phase 2 Unknown
48 enrolled
A Clinical Study of SKLB1028 Capsule in the Treatment of Recurrence/Refractory AML Patients
Phase 2 Unknown
30 enrolled
ProT4
Phase 2 Unknown
114 enrolled
SGI-110 and Donor Lymphocyte Infusions (DLI) After Allogeneic Stem Cell Transplantation
Phase 2 Unknown
40 enrolled
Decitabine,Cytarabine and Arsenic Trioxide for Acute Myeloid Leukemia With p53 Mutations
Phase 2 Unknown
100 enrolled
Efficacy and Safety Study of Recombinant Human Arginase 1 in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Phase 2 Unknown
25 enrolled
Efficacy Study of Inecalcitol With Decitabine in Acute Myeloid Leukemia Patients Unfit for Standard Chemotherapy
Phase 2 Unknown
110 enrolled
A Prospective, Interventional Study Assessing Response to Cytarabine, Daunorubicin and Etoposide (ADE) for First Relapse of Paediatric Acute Myeloid Leukemia
Phase 2 Unknown
84 enrolled
Clinical Trial of Ara-C, Aclarubicin Combined With PEG-G-CSF for Initial Treatment of AML Patients
Phase 2 Unknown
120 enrolled
NICE-BORA
Phase 2 Unknown
46 enrolled
BLAST
Phase 2 Unknown
194 enrolled
GFM-Chimio-Rev
Phase 2 Unknown
85 enrolled
Azacytidine Plus FLAG for Relapsed or Refractory AML
Phase 2 Unknown
37 enrolled
VNP40101M Followed by Cytarabine in Treating Older Patients With Acute Myeloid Leukemia
Phase 2 Unknown
85 enrolled
Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders
Phase 2 Unknown
52 enrolled
Cyclosporine and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Phase 2 Unknown
25 enrolled
Monoclonal Antibody in Treating Patients With Acute Myelogenous Leukemia
Phase 2 Unknown
Umbilical Cord Blood and Placental Blood Transplantation in Treating Patients With Hematologic Cancer or Aplastic Anemia
Phase 2 Unknown
30 enrolled